BCL2L1 and cancer: This compound was furtheroptimized by preparing an azaindole analogue to produce ABT199, aBcl-2 selective subnanomolar inhibitor of Bcl-2 that exhibited 3 ordersof magnitude less binding to Bcl-xL(Figure 2).23 As expected,ABT199 did not cause a reduction in platelets or cardiotoxicity andwas very active against several cancers that were dependent on Bcl-2for survival.